Home-based versus supervised group exercise in men with prostate cancer on androgen deprivation therapy : A randomized controlled trial and economic analysis
Copyright © 2023 Elsevier Ltd. All rights reserved..
INTRODUCTION: Differences between health outcomes, participation/adoption, and cost-effectiveness of home-based (HOME) interventions and supervised group-based training (GROUP) in men with prostate cancer (PC) on androgen deprivation therapy (ADT) are currently unknown. The objective of this study was to assess the clinical efficacy, adherence, and cost-effectiveness of HOME versus GROUP in men on ADT for PC.
MATERIALS AND METHODS: This was a multicentre, 2-arm non-inferiority randomized controlled trial and companion cost-effectiveness analysis. Men with PC on ADT were recruited from August 2016 to March 2020 from four Canadian centres and randomized 1:1 to GROUP or HOME. All study participants engaged in aerobic and resistance training four to five days weekly for six months. Fatigue [Functional Assessment of Cancer Therapy-Fatigue (FACT-F)] and functional endurance [6-min walk test (6MWT)] at six months were the co-primary outcomes. Secondary outcomes included quality of life, physical fitness, body composition, blood markers, sedentary behaviour, and adherence. Between-group differences in primary outcomes were compared to margins of 3 points for FACT-F and 40 m for 6MWT using a Bayesian analysis of covariance (ANCOVA). Secondary outcomes were compared with ANCOVA, Costs included Ministry of Health costs, program costs, patient out-of-pocket, and time costs.
TRIAL REGISTRATION: #NCT02834416.
RESULTS: Thirty-eight participants (mean [standard deviation (SD)] age, 70 [9.0] years) were enrolled (GROUP n = 20; HOME n = 18). There was an 89.8% probability that HOME was non-inferior to GROUP for both fatigue and functional endurance and a 9.5% probability that HOME reduced fatigue compared to GROUP (mean [SD] change, 12.1 [8.1] vs 3.6 [6.1]; p = 0.040) at six months. Adherence was similar among study arms. HOME was cost-saving (mean difference: -$4122) relative to GROUP.
DISCUSSION: A HOME exercise intervention appears non-inferior to GROUP for fatigue and functional endurance and requires fewer resources to implement. HOME appears to ameliorate fatigue more than GROUP, but has comparable effects on other clinically relevant outcomes. Although limited by sample size and attrition, these results support further assessment of home-based programs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Journal of geriatric oncology - 15(2023), 1 vom: 17. Jan., Seite 101646 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alibhai, Shabbir M H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Androgen Antagonists |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print-Electronic ClinicalTrials.gov: NCT02834416 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jgo.2023.101646 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364681926 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364681926 | ||
| 003 | DE-627 | ||
| 005 | 20231227140927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgo.2023.101646 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM364681926 | ||
| 035 | |a (NLM)37976654 | ||
| 035 | |a (PII)S1879-4068(23)00243-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alibhai, Shabbir M H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Home-based versus supervised group exercise in men with prostate cancer on androgen deprivation therapy |b A randomized controlled trial and economic analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02834416 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Differences between health outcomes, participation/adoption, and cost-effectiveness of home-based (HOME) interventions and supervised group-based training (GROUP) in men with prostate cancer (PC) on androgen deprivation therapy (ADT) are currently unknown. The objective of this study was to assess the clinical efficacy, adherence, and cost-effectiveness of HOME versus GROUP in men on ADT for PC | ||
| 520 | |a MATERIALS AND METHODS: This was a multicentre, 2-arm non-inferiority randomized controlled trial and companion cost-effectiveness analysis. Men with PC on ADT were recruited from August 2016 to March 2020 from four Canadian centres and randomized 1:1 to GROUP or HOME. All study participants engaged in aerobic and resistance training four to five days weekly for six months. Fatigue [Functional Assessment of Cancer Therapy-Fatigue (FACT-F)] and functional endurance [6-min walk test (6MWT)] at six months were the co-primary outcomes. Secondary outcomes included quality of life, physical fitness, body composition, blood markers, sedentary behaviour, and adherence. Between-group differences in primary outcomes were compared to margins of 3 points for FACT-F and 40 m for 6MWT using a Bayesian analysis of covariance (ANCOVA). Secondary outcomes were compared with ANCOVA, Costs included Ministry of Health costs, program costs, patient out-of-pocket, and time costs | ||
| 520 | |a TRIAL REGISTRATION: #NCT02834416 | ||
| 520 | |a RESULTS: Thirty-eight participants (mean [standard deviation (SD)] age, 70 [9.0] years) were enrolled (GROUP n = 20; HOME n = 18). There was an 89.8% probability that HOME was non-inferior to GROUP for both fatigue and functional endurance and a 9.5% probability that HOME reduced fatigue compared to GROUP (mean [SD] change, 12.1 [8.1] vs 3.6 [6.1]; p = 0.040) at six months. Adherence was similar among study arms. HOME was cost-saving (mean difference: -$4122) relative to GROUP | ||
| 520 | |a DISCUSSION: A HOME exercise intervention appears non-inferior to GROUP for fatigue and functional endurance and requires fewer resources to implement. HOME appears to ameliorate fatigue more than GROUP, but has comparable effects on other clinically relevant outcomes. Although limited by sample size and attrition, these results support further assessment of home-based programs | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Androgen deprivation therapy | |
| 650 | 4 | |a Economic analysis | |
| 650 | 4 | |a Group-based exercise | |
| 650 | 4 | |a Home-based exercise | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Androgens |2 NLM | |
| 700 | 1 | |a Papadopoulos, Efthymios |e verfasserin |4 aut | |
| 700 | 1 | |a Mina, Daniel Santa |e verfasserin |4 aut | |
| 700 | 1 | |a Ritvo, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Tomlinson, George |e verfasserin |4 aut | |
| 700 | 1 | |a Sabiston, Catherine M |e verfasserin |4 aut | |
| 700 | 1 | |a Durbano, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Bremner, Karen E |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarotto, James |e verfasserin |4 aut | |
| 700 | 1 | |a Matthew, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Warde, Padraig |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neill, Meagan |e verfasserin |4 aut | |
| 700 | 1 | |a Culos-Reed, S Nicole |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of geriatric oncology |d 2010 |g 15(2023), 1 vom: 17. Jan., Seite 101646 |w (DE-627)NLM203939069 |x 1879-4076 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:1 |g day:17 |g month:01 |g pages:101646 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jgo.2023.101646 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 1 |b 17 |c 01 |h 101646 | ||